HUMA
HEALTHCAREHumacyte Inc
AI Insight
What's Moving HUMA Today?
No stock-specific AI insight has been generated for HUMA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.55$2.84
$0.70
Fundamentals
Market Cap$249M
P/E Ratio—
EPS$-0.63
Dividend Yield—
Dividend / Share—
ROE-409.5%
Profit Margin—
Debt / Equity—
Trading
Volume46.1M
Avg Volume (10D)—
Shares Outstanding269.6M
HUMA News
27 articles- Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a BetYahoo Finance·Jun 19, 2026
- Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should KnowYahoo Finance·Jun 16, 2026
- Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should KnowYahoo Finance·Jun 15, 2026
- Humacyte's Bioengineered Blood Vessel Outperforms the Standard of Care for Women on Dialysis in Phase 3 Results Presented at the Society for Vascular Surgery Vascular Annual MeetingYahoo Finance·Jun 15, 2026
- Why Is Humacyte Stock Falling Thursday?Benzinga·Jun 11, 2026
- Humacyte launches public offering of common stockInvesting.com·Jun 11, 2026
- Humacyte, Inc. Announces Pricing of Public Offering of Common StockBenzinga·Jun 11, 2026
- Humacyte, Inc. Announces Proposed Public Offering of Common StockGlobeNewswire Inc.·Jun 11, 2026
- HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data ImpressesStocktwits·Jun 10, 2026
- Humacyte Says ATEV Met Late-Stage Study Endpoint in Interim Analysis, Launches Public Offering; Shares FallYahoo Finance·Jun 10, 2026
- Humacyte ATEV Met Superiority Primary Endpoint Compared to Standard of Care AV Fistula in Interim Analysis of V012 Phase 3 Study in Female Dialysis Access PatientsYahoo Finance·Jun 10, 2026
- Humacyte, Inc. Files Form 8-K with SEC: Company Details, Stock Information, and Regulatory DisclosuresMinichart·Jun 6, 2026
- Humacyte (HUMA) Q1 2025 Earnings TranscriptMotley Fool·Jun 1, 2026
- Humacyte (HUMA) Is Up 23.8% After Long-Term Self-Repair Dialysis Data - Has The Bull Case Changed?Yahoo Finance·May 31, 2026
- Humacyte (HUMA) Is Up 23.8% After New ATEV Self‑Repair Data And Phase 3 Timeline UpdateSimply Wall Street·May 30, 2026
- Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis AccessYahoo Finance·May 26, 2026
- Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans AffairsYahoo Finance·May 20, 2026
- Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage CommercializationYahoo Finance·May 19, 2026
- Humacyte (HUMA) Valuation Check As Q1 2026 Losses Meet Cost Cuts New Leadership And Global AgreementsSimply Wall Street·May 16, 2026
- Humacyte Inc (HUMA) Q1 2026 Earnings Call Highlights: Sales Surge and Strategic Expansions Amid ...Yahoo Finance·May 13, 2026
- Humacyte (HUMA) Q1 2026 Earnings TranscriptMotley Fool·May 13, 2026
- Humacyte Q1 Earnings Call HighlightsMarketbeat·May 13, 2026
- Humacyte Reports Q1 2026 Results: Full Earnings Call TranscriptYahoo Finance·May 13, 2026
- Humacyte, Inc. (HUMA) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 13, 2026
- Humacyte Announces First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 13, 2026
- Humacyte Receives Nasdaq Notice on Minimum Bid RequirementThe Globe and Mail·May 9, 2026
- Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc.·Mar 27, 2026
All 27 articles loaded
Price Data
Open$0.84
Previous Close$0.84
Day High$0.86
Day Low$0.70
52 Week High$2.84
52 Week Low$0.55
52-Week Range
$0.55$2.84
$0.70
Fundamentals
Market Cap$249M
P/E Ratio—
EPS$-0.63
Dividend Yield—
Dividend / Share—
ROE-409.5%
Profit Margin—
Debt / Equity—
Trading
Volume46.1M
Avg Volume (10D)—
Shares Outstanding269.6M
About Humacyte Inc
Humacyte Inc (HUMA) is a pioneering biotechnology company specializing in vascular and regenerative medicine, with a focus on the development of human acellular vessels (HAVs). These innovative off-the-shelf products address critical needs in vascular reconstruction and chronic disease management, enhancing patient outcomes while potentially lowering healthcare costs. Utilizing its advanced technology platform, Humacyte is strategically positioned to lead advancements in transplantation and tissue engineering, solidifying its role as a transformative force in the evolving medical therapies landscape.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—